T-knife
About:
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
Website: https://t-knife.com/
Top Investors: Andera Partners, RA Capital Management, Fidelity, EQT Life Sciences, Qatar Investment Authority
Description:
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.
Total Funding Amount:
$197M
Estimated Revenue Range:
$1M to $10M
Headquarters Location:
Berlin, Berlin, Germany
Founded Date:
2018-01-01
Founders:
Elisa Kieback, Thomas Blankenstein
Number of Employees:
51-100
Last Funding Date:
2021-08-02
IPO Status:
Private
Industries:
© 2025 bioDAO.ai